A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Follicular Lymphoma

Interventions

DRUG: Mosunetuzumab
DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Tociluzumab

Sponsor

Hoffmann-La Roche